New cocktail aims to stall breast cancer spread in Hard-to-Treat cases

NCT ID NCT07467330

Recruiting now Disease control Sponsor: Fujian Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether adding a chemotherapy drug (capecitabine) to a standard two-drug regimen (dalpiciclib plus hormone therapy) can slow cancer growth longer in people with HR+/HER2- breast cancer that has spread to internal organs. About 258 participants will be randomly assigned to either the three-drug combo or the two-drug combo. The main goal is to see how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dalpiciclib, capecitabine, and endocrine therapy (aromatase inhibitor or fulvestrant)
What this could lead to: If successful, this could offer a new treatment option that delays cancer progression for people with HR+/HER2- breast cancer that has spread to organs.
What could go wrong: This is an early-stage Phase 3 trial with 258 participants, so results may not apply to everyone. Adding capecitabine may increase side effects like hand-foot syndrome or fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Fujian Cancer Hosptial
RECRUITING

Fuzhou, Fujian, 350001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.